Table 3.

Bone histomorphometric parameters in the zoledronate and control groups

ParameterControl BaselineControl 12 moChanges,a Absolute/%Zoledronate BaselineZoledronate 12 moChanges,a Absolute/%P Value TransplantP Value Zoledronate versus ControlP Value Interaction
BV/TV, %24.7±6.525.3±8.60.6/2.424.4±6.320.1±5.9−4.3/−17.60.420.300.22
Tb.Sp, μm393±155429±16936/9.2387±106541±185154/39.80.0030.240.06
Tb.Th, μm125±24134±359/7.2120±27128±228/6.70.120.530.98
Tb.N, per mm2.1±0.61.9±0.4−0.1/−4.82.0±0.41.5±0.3−0.5/−25<0.0010.200.14
OV/BV, %7.0±6.26.8±9.2−0.2/−2.99.9±13.32.9±3.1−7/−70.70.070.820.09
OS/BS, %34.1±20.128.7±18.4−5.4/−15.839.1±19.519.2±14.4−19.9/−50.90.0020.640.06
O.Th, μm9.7±4.810.4±5.30.7/7.210.1±5.38.0±3.5−2.1/−20.80.560.360.24
Ob.S/BS, %7.9±6.47.2±5.7−0.7/−8.912.4±10.25.0±4.6−7.4/−59.70.0020.480.27
Oc.S/BS, %1.5±1.20.5±0.5−1.0/−66.72.5±1.90.4±0.4−2.1/−84<0.0010.180.06
ES/BS, %11.1±6.14.6±2.4−6.5/−58.613.0±6.54.0±2.2−9/−69.2<0.0010.570.23
BFR, μm3/μm2 per day0.06±0.060.04±0.03−0.02/−33.30.07±0.090.04±0.03−0.03/−42.90.040.830.71
Mlt, d225.2±245.8198.1±228.7−27.1/−12191.5±226.8170.7±343.3−20.8/−10.90.660.660.99
Ct.Th, μm735±1831105±446370/50.3714±1711234±385520/72.8<0.0010.620.24
Ct.Po, %8.0±3.45.1±3.0−2.9/−36.27.5±2.85.8±3.2−1.7/−22.70.001>0.990.32
  • P values are derived from a linear mixed model. BV/TV, bone volume/tissue volume; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness; Tb.N, trabecular number; OV/BV, osteoid volume/bone volume; OS/BS, osteoid surface; O.Th, osteoid thickness; Ob.S/BS, osteoblasts/bone surface; Oc.S/BS, osteoclasts/bone surface; ES/BS, erosion surface/bone surface; BFR, bone formation rate; Mlt, mineralization lag time; Ct.Th, cortical thickness; Ct.Po, cortical porosity.

  • a Changes according to groups.